Business Description
Prothena Corp PLC
ISIN : IE00B91XRN20
Share Class Description:
FRA:0PT: Ordinary SharesTotal Employee Number:
67Description
Prothena Corp PLC is a late-stage clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. Prothena is developing and applying its proprietary CYTOPE technology to target a broad spectrum of intracellular disease pathways in the brain and periphery. The company's pipeline includes both wholly-owned and partnered programs like Prasinezumab, Coramitug (PRX004), BMS-986446 (PRX005), PRX019, TDP-43 CYTOPE, and PRX012-TfR, being developed for the potential treatment of Parkinson's disease, ATTR amyloidosis with cardiomyopathy, Alzheimer's disease, Amyotrophic lateral sclerosis (ALS), and other neurodegenerative diseases.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 43.04 | |||||
Equity-to-Asset | 0.89 | |||||
Debt-to-Equity | 0.02 | |||||
Debt-to-EBITDA | -0.08 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 3/9 | |||||
Altman Z-Score | 2.03 | |||||
Beneish M-Score | -4.14 | |||||
WACC vs ROIC | ||||||
Growth Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -45.9 | |||||
3-Year EBITDA Growth Rate | -7.3 | |||||
3-Year EPS without NRI Growth Rate | -17.9 | |||||
3-Year FCF Growth Rate | -9.6 | |||||
3-Year Book Growth Rate | -24.1 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 96.08 |
Momentum Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 42.5 | |||||
9-Day RSI | 42.44 | |||||
14-Day RSI | 43.56 | |||||
3-1 Month Momentum % | -6.88 | |||||
6-1 Month Momentum % | 19.5 | |||||
12-1 Month Momentum % | 48.34 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 10.43 | |||||
Quick Ratio | 10.43 | |||||
Cash Ratio | 10.13 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -1.1 | |||||
Shareholder Yield % | 2.16 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Operating Margin % | -160.84 | |||||
Net Margin % | -260.92 | |||||
EBITDA Margin % | -159.36 | |||||
FCF Margin % | -139.23 | |||||
OCF Margin % | -139.07 | |||||
ROE % | -45.81 | |||||
ROA % | -39.29 | |||||
ROIC % | -216.3 | |||||
3-Year ROIIC % | 234.61 | |||||
ROC (Joel Greenblatt) % | -830.8 | |||||
ROCE % | -27.69 | |||||
Years of Profitability over Past 10-Year | 1 | |||||
Moat Score | 5 | |||||
Tariff Resilience Score | 6 |
GF Value Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Forward PE Ratio | 18.65 | |||||
PS Ratio | 7.84 | |||||
PB Ratio | 1.43 | |||||
Price-to-Tangible-Book | 1.42 | |||||
EV-to-EBIT | -1.27 | |||||
EV-to-EBITDA | -1.28 | |||||
EV-to-Revenue | 2.04 | |||||
EV-to-Forward-Revenue | 1.47 | |||||
EV-to-FCF | -1.45 | |||||
Price-to-GF-Value | 0.58 | |||||
Price-to-Median-PS-Value | 0.13 | |||||
| Price-to-Net-Current-Asset-Value | 1.48 | |||||
| Price-to-Net-Cash | 1.53 | |||||
Earnings Yield (Greenblatt) % | -78.74 | |||||
FCF Yield % | -18.52 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Prothena Corp PLC Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 50.096 | ||
| EPS (TTM) (€) | -2.431 | ||
| Beta | 0.9204 | ||
| 3-Year Sharpe Ratio | -0.84 | ||
| 3-Year Sortino Ratio | -0.98 | ||
| Volatility % | 38.74 | ||
| 14-Day RSI | 43.56 | ||
| 14-Day ATR (€) | 0.191144 | ||
| 20-Day SMA (€) | 7.6608 | ||
| 12-1 Month Momentum % | 48.34 | ||
| 52-Week Range (€) | 5.75 - 9.764 | ||
| Shares Outstanding (Mil) | 52.35 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Prothena Corp PLC Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Prothena Corp PLC Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-06 | In 98 days | ||
| Second quarter earnings results for 2026 | 2026-08-04 | In 4 days | ||
| General meeting for 2026 | 2026-05-14 16:00 | 7.89 (+0.00%) | ||
| First quarter earnings results for 2026 | 2026-05-07 | 9.42 (+0.00%) | ||
| Annual report for 2025 | 2026-02-27 | 7.15 (-2.72%) | ||
| Fourth quarter earnings conference call for 2025 | 2026-02-19 16:30 | 7.55 (+1.34%) | ||
| Fourth quarter earnings results for 2025 | 2026-02-19 | 7.55 (+1.34%) | ||
| Evercore Healthcare Conference | 2025-12-04 10:50 | 9.45 (+8.00%) | ||
| Piper Sandler Annual Healthcare Conference | 2025-12-03 13:00 | 8.70 (+0.58%) | ||
| Third quarter earnings results for 2025 | 2025-11-06 | 8.75 (+0.00%) |
Show
Entries
Prothena Corp PLC Frequently Asked Questions
What is Prothena Corp PLC(FRA:0PT)'s stock price today?
The current price of FRA:0PT is €7.34. The 52 week high of FRA:0PT is €9.76 and 52 week low is €5.75.
When is next earnings date of Prothena Corp PLC(FRA:0PT)?
The next earnings date of Prothena Corp PLC(FRA:0PT) is 2026-08-04 Est..
Does Prothena Corp PLC(FRA:0PT) pay dividends? If so, how much?
Prothena Corp PLC(FRA:0PT) does not pay dividend.
Press Release
Articles on Prothena Corp PLC
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers